Novo Nordisk Takes Legal Aim at Unapproved Semaglutide: 14 New U.S. Lawsuits

Pharmaceutical Law | IP Enforcement | Medical Safety On August 5, 2025, Danish pharmaceutical giant Novo Nordisk announced the launch of 14 new lawsuits in the United States against providers of unapproved compounded semaglutide—the active ingredient in its blockbuster weight-loss and diabetes treatments, Wegovy and Ozempic (Reuters). The litigation targets

Beyond Flesh and Code: The Legal Frameworks Needed for the Future of Biomechanical Medicine

BioTech Regulations & Laws | Global Health | Society Introduction: A Revolution in Motion Biomechanical medicine—a hybrid of robotics, biomedical engineering, artificial intelligence, and regenerative science—is reshaping the limits of what medicine can do. Smart prosthetics that learn from user behavior, bionic limbs with sensory feedback, neural implants that restore mobility,